SAFETY AND EFFICACY WERE
EVALUATED AT 52 WEEKS1

Patient exercising. Reductions at 52 weeks in symptoms of overactive bladder with GEMTESA®.

Reductions in UUI per 24 hours at 52 weeks1*

*Baseline: 3.18 for GEMTESA; 3.0 for active control.1

Urge urinary incontinence (UUI)1

Graph showing reductions in urge urinary incontinence (UUI) episodes. Reductions in UUI per 24 hours at 52 weeks with GEMTESA®.

*Baseline: 3.18 for GEMTESA; 3.0 for active control.1

Reductions in micturition frequency per 24 hours at 52 weeks1†

Baseline: 11.32 for GEMTESA; 11.33 for active control.1

Please see extension study design above.

Micturition frequency1

Graph showing reductions in micturition frequency. Micturition frequency at week 52 with GEMTESA®.

Baseline: 11.32 for GEMTESA; 11.33 for active control.1

Reductions in urgency episodes per 24 hours at 52 weeks1‡

Baseline: 8.0 for GEMTESA; 8.03 for active control.1

Please see extension study design above.

Urgency episodes1

Graph showing reductions in urgency episodes. Reductions in urgency episodes per 24 hours at 52 weeks with GEMTESA®.

Baseline: 8.0 for GEMTESA; 8.03 for active control.1

Reductions in UUI episodes of 100% at 52 weeks vs active control

§Data were based on an exploratory endpoint analysis of patients with 100% reduction in UUI from baseline at week 52 (N=143).1

Please see extension study design above.

100% reduction in UUI episodes1

Graph showing percent of patients with OAB wet with 100% reduction in urge urinary incontinence (UUI) episodes at 52 weeks with GEMTESA®.

§Data were based on an exploratory endpoint analysis of patients with 100% reduction in UUI from baseline at week 52 (N=143).1

Learn more about the mechanism of
action (MOA) of GEMTESA

See MOA
Patient. Learn about the mechanism of action (MOA) of GEMTESA®.
 

Reference: 1. Data on file. Urovant Sciences GmbH.